Immunovant unveils positive early data for PhII Graves' disease drug

Katherine Lewin

News Reporter

Immunovant’s drug for Graves’ disease showed a response rate that exceeded 50% in an initial cohort of patients in an ongoing 24-week Phase II clinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immunovant unveils positive early data for PhII Graves' disease drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Im­muno­vant un­veils pos­i­tive ear­ly da­ta for PhII Graves' dis­ease drug

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Immunovant unveils positive early data for PhII Graves' disease drug